MammoSite RTS

MammoSite RTS

A single-use catheter and radiation-solution source used to deliver local radiotheraphy (RT) to the tissue surrounding resected breast cancer. While the tumour is resected, a catheter is inserted into the tumour cavity before closure; after surgery, a radioactive liquid (Iotrex™) is delivered through the catheter to provide local RT directly to the tumour cavity.
References in periodicals archive ?
The American Society of Breast Surgeons MammoSite Registry(2) includes a total of 1,440 patients with early stage breast cancer, who were undergoing breast-conserving therapy and were treated with MammoSite RTS between May 2002 and July 2004.
The MammoSite RTS could make it easier for more women to consider the choice of lumpectomy and provides physicians with an important new tool for the practice of breast conservation therapy.
Products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer.
The MammoSite RTS is similar to radioactive implant therapy (called brachytherapy) for prostate cancer.
Settling this case allows us to focus resources on the continued expansion in the usage of MammoSite RTS and development of new applications for the treatment of breast and gynecological cancers.
Qualified patients with early-stage breast cancer were prospectively enrolled and treated using the MammoSite RTS as the sole modality for delivering accelerated partial breast irradiation (APBI).
The authors concluded that these data support the efficacy of MammoSite RTS in women with early stage breast cancer.
MammoSite RTS dramatically reduces treatment time to five days compared to 30-35 days for traditional whole breast external beam radiation therapy.
Marketed products include MammoSite RTS for breast cancer and GliaSite RTS for brain cancer.
MammoSite RTS is a minimally invasive balloon catheter that is inserted into the cavity created by a lumpectomy.
MammoSite RTS delivers radiation over a five day course of therapy only to the area directly surrounding the tumor site.